Servier has continued its push into oncology and search beyond its walls for innovation by striking a $130 million (€115 million) deal with Taiho Pharmaceutical. The fee, which is made up of an upfront payment and near-term milestone, will give Servier the rights to Taiho's treatment for refractory metastatic colorectal cancer.
Geneva-based GeNeuro, a spinout of the Institut Mérieux, has come up with a licensing deal that will deliver $47 million needed to complete a Phase IIb study of its experimental therapy for multiple sclerosis. And France's Servier gets an option on ex-U.S. and Japanese rights that's tied to a $408 million package of milestones along with a chance to buy an equity stake in the biotech sometime in the next year.
Just a few weeks after claiming success with a pair of late-stage studies of its prolonged dosing approach to diabetes, Boston-based Intarcia has followed up with a billion dollar-plus sized commercialization deal for ex-U.S. and Japan commercial rights with France's Servier.
Pharmacyclics and Servier are quietly walking away from a 5-year collaboration on a new cancer treatment, leaving the former company to go it alone on mid-stage oral drug with an uncertain future.
Ivabradine, a heart rate-reducing drug from Servier and Amgen, failed to beat placebo in a huge study of patients with coronary artery disease, potentially clouding its future on two continents.
European regulators are getting the hang of levying pay-for-delay penalties, rolling up 6 companies in its latest action and fining them more than half a billion dollars in the process.
European antitrust regulators may have been a little late to the party when it comes to pay-for-delay actions but are making up for lost time. Sources are saying they will levy fines against French drugmaker Servier and Teva Pharmaceutical Industries next month for delaying the launch of generic blood pressure meds.
France's Servier has struck up a deal with Novartis to develop oncology drugs that invade tumors and lead them to self-destruct.
A busy Servier wants to explore Celladon's technology to see if there are some small molecule applications to diabetes and other metabolic conditions that warrant clinical development.
The French biotech announced this morning that it will collaborate with Paris-based Cellectis on UCART19, an engineered T cell with a chimeric antigen receptor for leukemia and lymphomas, as well as 5 other such programs. Servier is paying Cellectis $10 million down and up to $140 million per program in milestones in its gamble on the biotech's approach.